Gene Expression Signature Predicts Immune-Related Adverse Events in Melanoma Patients
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 12, 2024 -- A gene expression signature in peripheral CD4+ T-cells can predict severe immune-related adverse events (irAEs) among melanoma patients treated with ipilimumab/nivolumab, according to a study published online Aug. 8 in Clinical Cancer Research.
Kelsey R. Monson, Ph.D., from the Perlmutter Cancer Center at NYU Langone Health in New York City, and colleagues examined postsurgical, pre-immune checkpoint inhibitor treatment peripheral CD4+ and CD8+ T-cells from melanoma patients in a clinical trial (CheckMate-915) treated with adjuvant nivolumab (130 patients) or ipilimumab/nivolumab (COMBO; 82 patients). Baseline differences associated with severe (grade 3 to 5) irAEs were tested and a predictive model was constructed.
The researchers found significant enrichment of the spleen tyrosine kinase (SYK) pathway in peripheral CD4+ cells, which was associated with severe irAEs in COMBO-treated patients. Severe irAE COMBO patients were predicted by this gene-expression signature with 73 percent accuracy, independent of disease recurrence. The irAE predictive model that incorporated this gene-expression signature had 82 percent accuracy.
"Predictive information of this kind is critically important to oncologists and patients to help guide their immunotherapy decisions, to either minimize these side effects by taking additional precautions or choose alternative immunotherapies," Monson said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Prevalence of Skin Cancer Varies for Sexual Minority, Heterosexual Adults
FRIDAY, July 19, 2024 -- With respect to their lifetime prevalence of skin cancer, sexual minority (SM) adults differ across racial and ethnic groups and among males and females...
Rural Residents Continue to Have Higher Odds of Skin Cancer
TUESDAY, July 9, 2024 -- Urban-rural disparities in skin cancer prevalence continue to persist, according to a study published in the June issue of the Journal of Drugs in...
No Link Seen Between Exposure to Immunosuppressive Therapy, Cancer in IBD Patients
TUESDAY, June 11, 2024 -- There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.